	US 11,952,419 B2
	Reagents and methods for treating cancer and autoimmune disease
Laijun Lai, Farmington, CT (US)
Assigned to UNIVERSITY OF CONNECTICUT, Farmington, CT (US)
Appl. No. 17/057,429
Filed by UNIVERSITY OF CONNECTICUT, Farmington, CT (US)
PCT Filed Jul. 8, 2019, PCT No. PCT/US2019/040759 § 371(c)(1), (2) Date Nov. 20, 2020, PCT Pub. No. WO2020/014097, PCT Pub. Date Jan. 16, 2020.
Claims priority of provisional application 62/696,142, filed on Jul. 10, 2018.
Prior Publication US 2021/0206849 A1, Jul. 8, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); C07K 14/705 (2006.01)

CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); A61P 37/00 (2018.01); C07K 14/70503 (2013.01); A61K 38/00 (2013.01); A61K 2039/507 (2013.01)]

19 Claims

1. An isolated anti-human CD300c antibody, or fragment thereof, comprising each of the following complementarity determining regions (CDRs):

Heavy chain CDR1 (H-CDR1) comprising the amino acid sequence IYGMN (SEQ ID NO: 10);

Heavy chain CDR2 (H-CDR2) comprising the amino acid sequence WINTYT (SEQ ID NO: 11);

Heavy chain CDR3 (H-CDR3) comprising the amino acid sequence ARSRFAY (SEQ ID NO: 12);

Light chain CDR1 (L-CDR1) comprising the amino acid sequence KASQNVGTNVA (SEQ ID NO: 13);

Light chain CDR2 (L-CDR2) comprising the amino acid sequence SASYRYS (SEQ ID NO:14); and

Light chain CDR3 (L-CDR3) comprising the amino acid sequence QQYNSYPLT (SEQ ID NO:15).